Immunocore Secures $130 Million Series B Financing
02 mars 2020 07h00 HE
|
Immunocore Limited
Immunocore Secures $130 Million Series B Financing Led by General Atlantic, funding will expand novel scientific platform and advance proprietary pipeline of ImmTAX™ molecules into the clinic ...
Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech
19 nov. 2018 07h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech First-in-human clinical trial of IMC-C103C scheduled to commence in 2019 in multiple...
Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech
19 nov. 2018 02h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech First-in-human clinical trial of IMC-C103C scheduled to commence in 2019 in multiple...
Immunocore strengthens IP position in the field of TCR-based therapeutics
05 sept. 2018 07h00 HE
|
Immunocore Limited
Immunocore strengthens IP position in the field of TCR-based therapeutics Notice of Allowance received from US patent and trademark office relating to ImmTAC® platform (Oxford, UK and...
Immunocore strengthens IP position in the field of TCR-based therapeutics
05 sept. 2018 02h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore strengthens IP position in the field of TCR-based therapeutics Notice of Allowance received from US patent and trademark office relating to ImmTAC® platform (Oxford, UK and...
Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours
20 août 2018 07h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours Study of IMCnyeso in NSCLC, Bladder Cancer, Melanoma and Synovial Sarcoma is the first in GSK...
Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours
20 août 2018 02h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours Study of IMCnyeso in NSCLC, Bladder Cancer, Melanoma and Synovial Sarcoma is the first in GSK...
Immunocore Announces Leadership Change
08 févr. 2018 10h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore Announces Leadership Change Oxford, UK and Philadelphia, USA, 8 February 2018 Immunocore Limited, the soluble TCR company developing first-in-class biologics that...
Immunocore Strengthens its Board with Appointments of Laura Wade-Gery and Kristine Peterson as Non-Executive Directors
04 janv. 2018 07h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore Strengthens its Board with Appointments of Laura Wade-Gery and Kristine Peterson as Non-Executive Directors (Oxford, UK and Conshohocken, US, 4 January 2018)...
Immunocore Strengthens its Board with Appointments of Laura Wade-Gery and Kristine Peterson as Non-Executive Directors
04 janv. 2018 02h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore Strengthens its Board with Appointments of Laura Wade-Gery and Kristine Peterson as Non-Executive Directors (Oxford, UK and Conshohocken, US, 4 January 2018)...